Company intelligence / Profile preview

Cann Group Limited

Melbourne, Victoria, Australiacanngrouplimited.com ↗

Ownership: Private
Development stage: Commercial

Overview

Leading Australian medicinal cannabis producer focused on R&D-driven B2B/B2C models

Therapeutic areas: OtherNeurology
Modalities: Plant-derived cannabinoidsOral microbead capsules
Industry: Biotech

Drug pipeline

1 asset

Satipharm CBD

Unknown

Partnerships

GlaxoSmithKline Consumer Healthcare – evaluation agreement for potential commercialization of the Satipharm CBD capsule in Australia as an OTC productChemist Warehouse – new supply agreements to expand access to products through retail pharmacy outlets in QueenslandGrodan – supplier partnership supporting cultivation operations at Mildura facility

Beyond the preview

Go deeper on Cann Group Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cann Group Limited.

Explore the full profile